中药改善非小细胞肺癌患者EGFR-TKIs获得性耐药研究现状及其中医病机探析  

Current status of research on traditional Chinese medicine improving acquired resistance to EGFR⁃TKIs in patients with non⁃small cell lung cancer and analysis of TCM pathogenesis

作　　者：磨炼 慕晓艳[1] 李和根[1] MO Lian;MU Xiaoyan;LI Hegen(Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院,上海200032

出　　处：《上海中医药杂志》2023年第4期24-28,共5页Shanghai Journal of Traditional Chinese Medicine

基　　金：上海市科委上海市中医肿瘤临床医学研究中心建设项目(21MC1930500);上海市卫健委上海市临床重点专科建设项目(shslczdzk03701);上海市浦东新区卫健委卫生计生科研项目(PW2019E-1);上海市闵行区卫健委中医专科(专病)联盟建设项目(2021-2023年)(LM07);上海中医药大学附属龙华医院爱建捐赠基金资助项目(Y1910);上海中医药大学附属龙华医院龙医学者临床科技创新项目(KC2022015)。

摘　　要：非小细胞肺癌常见致癌因素为表皮生长因子受体(EGFR)基因突变,表皮生长因子受体-酪氨酸激酶抑制剂(EGFRTKIs)的出现为患者带来了新的希望,但获得性耐药的产生是限制其疗效的主要问题。通过总结中药改善非小细胞肺癌患者EGFR-TKIs获得性耐药的研究现状,分析现阶段研究的特点与不足,探析其背后的中医病机,提出“毒邪为病”与“正气为虚”为关键因素并作出展望,以期为中医药治疗非小细胞肺癌患者EGFR-TKIs获得性耐药提供诊疗思路和用药依据。Epidermal growth factor receptor(EGFR)mutation is a common carcinogenic factor in non-small cell lung cancer(NSCLC).The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)has brought new hope to patients,but acquired drug resistance is a major problem that limits the efficacy.By summarizing the research on traditional Chinese medicine(TCM)improving acquired resistance to EGFR-TKIs in NSCLC patients,analyzing the characteristics and shortcomings of the current research,and exploring the underlying TCM pathogenesis,we propose that“toxic pathogen as the cause”and“healthy qi being in deficiency”are the key factors and we prospect about the future research work to provide diagnostic ideas and medication basis for the TCM treatment of acquired resistance to EGFR-TKIs in NSCLC patients.

关 键 词：非小细胞肺癌 表皮生长因子受体-酪氨酸激酶抑制剂 获得性耐药 中药 中医病机 

分 类 号：R273[医药卫生—中西医结合]